AU2002251010A1 - Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists - Google Patents

Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists

Info

Publication number
AU2002251010A1
AU2002251010A1 AU2002251010A AU2002251010A AU2002251010A1 AU 2002251010 A1 AU2002251010 A1 AU 2002251010A1 AU 2002251010 A AU2002251010 A AU 2002251010A AU 2002251010 A AU2002251010 A AU 2002251010A AU 2002251010 A1 AU2002251010 A1 AU 2002251010A1
Authority
AU
Australia
Prior art keywords
anticholinergics
receptor antagonists
compositions based
medicament compositions
novel medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002251010A
Other languages
English (en)
Inventor
Christopher John Montague Meade
Michel Pairet
Michael Paul Pieper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical BOEHRINGER INGELHEIM PHARMA
Publication of AU2002251010A1 publication Critical patent/AU2002251010A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2002251010A 2001-03-08 2002-02-26 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists Abandoned AU2002251010A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10111058A DE10111058A1 (de) 2001-03-08 2001-03-08 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten
DE10111058.8 2001-03-08
PCT/EP2002/001987 WO2002069944A2 (fr) 2001-03-08 2002-02-26 Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de recepteurs nk1

Publications (1)

Publication Number Publication Date
AU2002251010A1 true AU2002251010A1 (en) 2002-09-19

Family

ID=7676673

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002251010A Abandoned AU2002251010A1 (en) 2001-03-08 2002-02-26 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists

Country Status (7)

Country Link
EP (1) EP1370293A2 (fr)
JP (1) JP2004519484A (fr)
AU (1) AU2002251010A1 (fr)
CA (1) CA2439915A1 (fr)
DE (1) DE10111058A1 (fr)
MX (1) MXPA03008051A (fr)
WO (1) WO2002069944A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214264A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
DE10230750A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholonergika und NK1-Rezeptor-Antagonisten
WO2005004875A1 (fr) * 2003-07-14 2005-01-20 Sankyo Company, Limited Composition medicinale a administration pulmonaire
JP2006160639A (ja) * 2004-12-06 2006-06-22 Sankyo Co Ltd ニューロキニン受容体拮抗剤と抗コリン剤の併用
ITRM20120331A1 (it) * 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
WO2015111627A1 (fr) * 2014-01-21 2015-07-30 味の素株式会社 Acide aminé de sucre et application associée

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3429338B2 (ja) * 1992-07-27 2003-07-22 杏林製薬株式会社 新規なアリールグリシンアミド誘導体及びその製造法
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
DE19608665A1 (de) * 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
EP1085875A1 (fr) * 1998-06-11 2001-03-28 MERCK SHARP & DOHME LTD. Utilisation d'un antagoniste du recepteur nk-1 dans le traitement des troubles psychiatriques

Also Published As

Publication number Publication date
MXPA03008051A (es) 2003-12-04
DE10111058A1 (de) 2002-09-12
EP1370293A2 (fr) 2003-12-17
WO2002069944A2 (fr) 2002-09-12
CA2439915A1 (fr) 2002-09-12
JP2004519484A (ja) 2004-07-02
WO2002069944A3 (fr) 2003-10-02

Similar Documents

Publication Publication Date Title
AU2002347022A1 (en) Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
HUP0500107A3 (en) 1-alkyl-1-azoniabicyclo[2.2.2.]octane carbamate derivatives, pharmaceutical compositions comprising thereof and their use as muscarinic receptor antagonists
AU2002341834A1 (en) Antagonists
AUPR769501A0 (en) Cytokine receptor 1
HUP0302969A3 (en) Npyy5 antagonists, pharmaceutical compositions containing them and their use
AU2002235224A1 (en) Muscarinic antagonists
AU4288000A (en) Modified amino-acid amides as cgrp antagonists
AU6031001A (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
AU2001296013A1 (en) Pgd2 receptor antagonistic pharmaceutical compositions
AU2002210575A1 (en) Novel medicament compositions based on anticholinergics and corticosteroids
AU2003255501A1 (en) Cxcr4 receptor antagonists
AU2002258221A1 (en) Medicinal composition
AU2002365655A1 (en) 5-ht7 receptor antagonists
IL163939A0 (en) Nk1 antagonists
AU2003267088A1 (en) Chemokine receptor antagonists as therapeutic agents
PL370799A1 (en) Aminotetralin derivatives as muscarinic receptor antagonists
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
EP1407780A4 (fr) Compositions hemostatiques pharmaceutiquement stables
AU2002251010A1 (en) Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
AU2003300904A1 (en) Antagonists for human prolactin
AU2002347552A1 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU5786300A (en) Muscarinic antagonists
AU2003256793A1 (en) Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses
AU2002321808A1 (en) Dental compositions
AU2002359524A1 (en) P2x7 receptor antagonists

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase